United States Medical Cervical Cancer Diagnostics Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Cervical Cancer Diagnostics Market is growing with a high CAGR during the forecast period 2023-2030.

Key Development:

United States: Recent Industry Developments

✅ In September 2025, PHASE Scientific launched the world's largest urine-based HPV screening clinical study, marking a significant step in non-invasive cervical cancer diagnostics.

✅ In August 2025, the Bill & Melinda Gates Foundation announced a commitment of up to $180 million over four years to accelerate global HPV vaccine uptake and develop new diagnostic tools, including for cervical cancer.

✅ In May 2025, the U.S. FDA approved the Teal Wand, the first at-home cervical cancer screening test. This device allows women to self-collect samples at home for HPV testing, aiming to increase screening accessibility and comfort.

Japan: Recent Industry Developments

✅ In September 2025, Japan's cell cancer vaccine market was valued at $0.34 billion, with projections to reach $0.57 billion by 2034, indicating a growing focus on immunotherapy.

✅ In August 2025, Japan's next-generation cancer diagnostics market was expected to grow from $608.6 million in 2024 to over $2 billion by 2033, with next-generation sequencing leading the growth.

✅ In August 2025, Japan's colposcopy market was projected to reach over $66 million by 2033, driven by technological advancements and increased cancer incidence.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/cervical-cancer-diagnostics-market?sb

Recent Mergers and Acquisitions:

United States: Recent Mergers & Acquisitions

✅ In June 2025, Hera Biotech acquired HeraFem, a point-of-care cervical cancer diagnostic device developed by Hera Diagnostics. This acquisition enhances Hera Biotech's women's health platform, adding a device with 91% sensitivity for detecting cervical intraepithelial neoplasia grade 2 (CIN2+) lesions through electrical and optical spectroscopy combined with AI algorithms.

✅ In May 2025, Teal Health launched the Teal Wand, the first FDA-approved at-home cervical cancer screening device. This device allows individuals to collect their own vaginal samples to test for HPV, offering a less invasive alternative to traditional Pap smears.

✅ In December 2024, Metropolis Healthcare Limited announced its acquisition of Core Diagnostics, based in Delhi NCR, for USD 29.62 million. This acquisition aims to strengthen Metropolis' cancer testing services and enhance its footprint across Northern and Eastern India.

Key Players:

=> F. Hoffmann-La Roche AG, QIAGEN, DaAnGene, Molbio Diagnostics, Cepheid, Norgen Biotek Corp., Atila Diagnostics, Abbott Laboratories, Life Cell International, and Sansure Biotech among others.

Growth Forecast Projected:

The Global Cervical Cancer Diagnostics Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Cervical Cancer Diagnostics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cervical-cancer-diagnostics-market

Key Segments:

➥ By Test Type: Pap Smear Test, HPV Test, Colposcopy Test, Imaging Tests, Cervical Biopsies, Biomarker Testing

➥ By Age Group: 20-30 years, Above 30 years

➥ By Cancer Type: Squamous Cell Carcinoma, Adenocarcinoma, Small Cell Neuroendocrine Carcinoma

➥ By Stage: Stage I, Stage II, Stage III, Stage IV

➥ By End User: Hospitals and Clinics, Cancer Diagnostic Centers, Cancer Research Institutes

Regional Analysis for Cervical Cancer Diagnostics Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Cervical Cancer Diagnostics producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Cervical Cancer Diagnostics revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cervical-cancer-diagnostics-market?sb

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.